A Pilot Study Comparing HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas by Whole Exome Sequencing

• Published in: ISRN oncology Vol. 2012; no. 2012; pp. 1 - 9
• Main Authors: Basmaji, John, Dhaliwal, Sandeep, Xu, Wei, Yoo, John, Chan-Seng-Yue, Michelle, Nichols, Anthony C., Szeto, Christopher C. T., Dowthwaite, Samuel A., Todorovic, Biljana, Starmans, Maud H. W., Lambin, Philippe, Palma, David A., Fung, Kevin, Franklin, Jason H., Wehrli, Bret, Kwan, Keith, Koropatnick, James, Mymryk, Joe S., Boutros, Paul C., Barrett, John W.
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Puplishing Corporation 2012; International Scholarly Research Network; Hindawi Limited
• Subjects: biomarkers; Blood; Cancer; DNA; Exons; Genomes; Head & neck cancer; Head and neck; Head and neck cancer; Health sciences; Human papillomavirus; Infection; Medical research; mucin; Mutation; Oncology; Patients; squamous cell carcinoma; Surgery; Tongue; Tonsil; Tumors; Zinc finger proteins
• ISSN: 2090-5661; 2090-567X; 2090-567X
• DOI: 10.5402/2012/809370

Background. Next-generation sequencing of cancers has identified important therapeutic targets and biomarkers. The goal of this pilot study was to compare the genetic changes in a human papillomavirus- (HPV-)positive and an HPV-negative head and neck tumor. Methods. DNA was extracted from the blood and primary tumor of a patient with an HPV-positive tonsillar cancer and those of a patient with an HPV-negative oral tongue tumor. Exome enrichment was performed using the Agilent SureSelect All Exon Kit, followed by sequencing on the ABI SOLiD platform. Results. Exome sequencing revealed slightly more mutations in the HPV-negative tumor (73) in contrast to the HPV-positive tumor (58). Multiple mutations were noted in zinc finger genes (ZNF3, 10, 229, 470, 543, 616, 664, 638, 716, and 799) and mucin genes (MUC4, 6, 12, and 16). Mutations were noted in MUC12 in both tumors. Conclusions. HPV-positive HNSCC is distinct from HPV-negative disease in terms of evidence of viral infection, p16 status, and frequency of mutations. Next-generation sequencing has the potential to identify novel therapeutic targets and biomarkers in HNSCC.